FDA To Reassess Avandia Risk After Revisited Study

Law360, New York (April 12, 2013, 6:01 PM EDT) -- The U.S. Food and Drug Administration announced Friday it would consider another regulatory review of GlaxoSmithKline PLC’s former blockbuster diabetes treatment Avandia, which is restricted over cardiovascular risks, following a re-examination of data from a previous trial for the drug.

According to the announcement, scheduled to be published Monday in the Federal Register, the FDA will convene a meeting in June with its endocrinologic and metabolic drugs advisory committee and its drug safety and risk management advisory committee in order to discuss the results of an...
To view the full article, register now.